Teva Pharmaceutical Industries Limited American DE (NYSE:TEVA) Has Decline in Shorts

July 14, 2018 - By Kyle Williams

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

The stock of Teva Pharmaceutical Industries Limited American DE (NYSE:TEVA) registered a decrease of 3.69% in short interest. TEVA’s total short interest was 53.78 million shares in July as published by FINRA. Its down 3.69% from 55.84M shares, reported previously. With 9.00 million shares average volume, it will take short sellers 6 days to cover their TEVA’s short positions. The short interest to Teva Pharmaceutical Industries Limited American DE’s float is 5.71%.

The stock decreased 1.85% or $0.44 during the last trading session, reaching $23.29. About 9.08M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 22.74% since July 14, 2017 and is downtrending. It has underperformed by 35.31% the S&P500.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company has market cap of $23.72 billion. It operates through two divisions, Generic Medicines and Specialty Medicines. It currently has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 19 analysts covering Teva Pharma (NYSE:TEVA), 5 have Buy rating, 3 Sell and 11 Hold. Therefore 26% are positive. Teva Pharma has $2800 highest and $13.0 lowest target. $19.68’s average target is -15.50% below currents $23.29 stock price. Teva Pharma had 32 analyst reports since January 16, 2018 according to SRatingsIntel. The stock has “Hold” rating by Jefferies on Tuesday, March 20. Leerink Swann maintained the shares of TEVA in report on Friday, January 26 with “Sell” rating. The rating was upgraded by Credit Suisse to “Outperform” on Monday, February 12. The firm has “Sell” rating given on Tuesday, January 30 by RBC Capital Markets. The stock has “Sell” rating by Leerink Swann on Monday, June 11. Guggenheim maintained the shares of TEVA in report on Tuesday, March 13 with “Hold” rating. The stock has “Hold” rating by RBC Capital Markets on Friday, February 9. Mizuho maintained the shares of TEVA in report on Monday, May 7 with “Buy” rating. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Hold” rating given on Friday, February 9 by Gabelli. The rating was maintained by RBC Capital Markets with “Sell” on Wednesday, January 24.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: Fool.com which released: “3 Warren Buffett Stocks Worth Buying Now” on July 14, 2018, also Businesswire.com with their article: “Teva to Report Second Quarter 2018 Financial Results on August 2, 2018” published on July 11, 2018, Seekingalpha.com published: “Teva: Shopping For Generic Bonds” on July 03, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: Streetinsider.com and their article: “Teva Pharma (TEVA) PT Raised to $25 at Cantor Fitzgerald” published on July 13, 2018 as well as Finance.Yahoo.com‘s news article titled: “Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play” with publication date: June 15, 2018.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: